These findings differ from those of our previous studies with hcAbs directed against human CD38, in which we found that the 22 nanobody-based hcAbs directed against 3 different epitopes of human CD38 showed little if any capacity to induce CDC against different human CD38 expressing lymphoma cell lines (35, 51). The gene discussed is CD38; the disease is lymphoma.